DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
CNMD logo

CONMED Corporation Stock Price

NYSE:CNMD Community·US$1.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

CNMD Share Price Performance

US$46.30
-6.60 (-12.48%)
​
US$45.50
Fair Value
US$46.30
-6.60 (-12.48%)
1.8% overvalued intrinsic discount
US$45.50
Fair Value
Price US$46.30
AnalystConsensusTarget US$45.50
AnalystHighTarget US$49.00
AnalystLowTarget US$43.00
Fri, 14 Aug 26
Fair ValueUS$45.50
Share Pricen/a

CNMD Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$45.5 1.8% overvalued intrinsic discount

Minimally Invasive Surgeries And Robotics Will Boost Global Healthcare

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$49 5.5% undervalued intrinsic discount

Global Aging And Minimally Invasive Trends Will Empower Future Markets

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$43 7.7% overvalued intrinsic discount

Rising Costs And Supply Risks Will Impair Future Performance

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
CNMD logo
CONMED
7.7% overvalued intrinsic discount

Rising Costs And Supply Risks Will Impair Future Performance

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 3 Sep
Read Narrative
CNMD logo
CONMED
1.8% overvalued intrinsic discount

Minimally Invasive Surgeries And Robotics Will Boost Global Healthcare

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 14 Aug
Read Narrative
CNMD logo
CONMED
5.5% undervalued intrinsic discount

Global Aging And Minimally Invasive Trends Will Empower Future Markets

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 31 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
CNMD logo

CNMD: Sale Hopes Will Be Tested By Debt Burden Through 2026

Fair Value: US$43 7.7% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
CNMD logo

CNMD: Gastro Exit And Potential Sale Interest Will Shape Future Upside

Fair Value: US$45.5 1.8% overvalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
CNMD logo

CNMD: Potential Sale And Surgical Reset Will Shape Next Chapter

Fair Value: US$49 5.5% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Undervalued with moderate growth potential.

3 Risks
3 Rewards
View Full Analysis

CONMED Corporation Key Details

US$1.4b

Revenue

US$609.3m

Cost of Revenue

US$762.3m

Gross Profit

US$705.8m

Other Expenses

US$56.5m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
1.89
55.58%
4.12%
80.0%
View Full Analysis

About CNMD

Founded
1970
Employees
3900
CEO
Patrick Beyer
WebsiteView website
www.conmed.com

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.

Recent CNMD News & Updates

User avatar
Narrative Update • Sep 03

CNMD: Sale Hopes Will Be Tested By Debt Burden Through 2026

Analysts have raised their fair value estimate for CONMED to $43.00, reflecting recent price target moves toward $45.00 and research commentary that highlights cleaner financials, recurring revenue strengths, and private equity interest despite ongoing execution and growth headwinds. Analyst Commentary Recent research on CONMED points to a mixed setup.
Seeking Alpha • Aug 18

CONMED Corporation: Organic Growth Is Masked By Divestitures

Summary Conmed's headline growth appeared flat at $343 million in the last quarter, but organic growth actually increased by 6%, with the leading segment being the orthopedic surgery business. Growth was offset by the divestiture of the GI business; as a result, growth metrics look poor with a quant rating of F and below the sector growth. When I adjust for organic growth, impressive profitability, and a buyback story, Conmed stock looks highly undervalued below the sector multiple. and I am rating it a buy. Read the full article on Seeking Alpha
User avatar
Narrative Update • Aug 14

CNMD: Gastro Exit And Potential Sale Interest Will Shape Future Upside

Analysts have raised the implied fair value for CONMED to $45.50 from $39.60, reflecting higher Street price targets clustered around $45 after recent Q2 outperformance, one-time tariff benefits, and renewed interest from potential financial and strategic buyers. Analyst Commentary Recent research on Conmed shows a split between investors focused on potential sale value and those focused on execution risks and relative appeal within medtech.

Recent updates

No updates

CONMED Corporation Competitors

HQY logo

HealthEquity

Symbol: NasdaqGS:HQY
Market cap: US$7.8b
HNGE logo

Hinge Health

Symbol: NYSE:HNGE
Market cap: US$7.1b
PACS logo

PACS Group

Symbol: NYSE:PACS
Market cap: US$7.1b
CHE logo

Chemed

Symbol: NYSE:CHE
Market cap: US$6.7b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide